Published in J Vasc Res on August 30, 1996
Matrix metalloproteinases: pathways of induction by bioactive molecules. Heart Fail Rev (2004) 1.10
Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin. Hypertension (2009) 0.99
Influence of aldosterone on collagen synthesis and proliferation of rat cardiac fibroblasts. Br J Pharmacol (2001) 0.82
Genomic and rapid effects of aldosterone: what we know and do not know thus far. Heart Fail Rev (2016) 0.75
Is pretreatment with Beta-blockers beneficial in patients with acute coronary syndrome? Cardiology (2009) 2.08
Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog Retin Eye Res (2001) 1.76
Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med (1986) 1.60
Changes of immunoregulatory cells induced by psychological and physical stress: relationship to plasma catecholamines. Clin Exp Immunol (1984) 1.45
Simple point-of-care risk stratification in acute coronary syndromes: the AMIS model. Heart (2008) 1.45
Vascular dysregulation: a principal risk factor for glaucomatous damage? J Glaucoma (1999) 1.45
Calcium binding to fluorescent calcium indicators: calcium green, calcium orange and calcium crimson. Biochem Biophys Res Commun (1991) 1.44
Angiotensin II-receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction. Eur Heart J (1996) 1.42
The impact of statin treatment on presentation mode and early outcomes in acute coronary syndromes. Cardiology (2007) 1.40
Comparative effects of haemodialysis and haemofiltration on plasma atrial natriuretic peptide. Nephrol Dial Transplant (1989) 1.39
Expression of cell adhesion molecule T-cadherin in the human vasculature. Histochem Cell Biol (2001) 1.38
Extracellular matrix deposition by primary human lung fibroblasts in response to TGF-beta1 and TGF-beta3. Am J Physiol (1999) 1.36
Correlation of platelet calcium with blood pressure. Effect of antihypertensive therapy. N Engl J Med (1984) 1.34
Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression. J Clin Invest (1994) 1.33
Trigeminal cardiac reflex: new thinking model about the definition based on a literature review. Medicine (Baltimore) (2015) 1.30
Kinetics of calcium binding to fluo-3 determined by stopped-flow fluorescence. Biochem Biophys Res Commun (1989) 1.30
Six S100 genes are clustered on human chromosome 1q21: identification of two genes coding for the two previously unreported calcium-binding proteins S100D and S100E. Proc Natl Acad Sci U S A (1993) 1.30
A new locus for arrhythmogenic right ventricular cardiomyopathy (ARVD2) maps to chromosome 1q42-q43. Hum Mol Genet (1995) 1.29
Altered expression of the Ca(2+)-binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta (1996) 1.29
Different translocation of three distinct PKC isoforms with tumor-promoting phorbol ester in human platelets. Biochem Biophys Res Commun (1991) 1.17
Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci U S A (1996) 1.12
Calcium and magnesium binding to rat parvalbumin. Eur J Biochem (1994) 1.09
The vasodilator potency of atrial natriuretic peptide in man. Circulation (1987) 1.07
Enhancement of calcium influx in human platelets by CGP 28392, a novel dihydropyridine. Biochem Biophys Res Commun (1984) 1.06
Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine. J Am Coll Cardiol (1986) 1.05
S100 alpha, CAPL, and CACY: molecular cloning and expression analysis of three calcium-binding proteins from human heart. Biochemistry (1992) 1.01
Nerve growth factor induces mast cell degranulation without changing intracellular calcium levels. FEBS Lett (1986) 0.97
Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am J Med (1984) 0.94
Absorption of an aqueous solution of a new synthetic somatostatin analogue administered to man by gavage. Eur J Clin Pharmacol (1987) 0.92
Factors influencing the hypotensive effects of calcium antagonists. Hypertension (1983) 0.92
Characterization of the human and mouse cDNAs coding for S100A13, a new member of the S100 protein family. Biochem Biophys Res Commun (1996) 0.91
Arterial vasodilator, systemic and coronary hemodynamic effects of nisoldipine in congestive heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol (1987) 0.91
Myocardial tissue characterization in heart failure by real-time integrated backscatter. Eur J Ultrasound (1999) 0.90
LDL induces intracellular signalling and cell migration via atypical LDL-binding protein T-cadherin. Mol Cell Biochem (2005) 0.90
Ca2+ as messenger of 5HT2-receptor stimulation in human blood platelets. Naunyn Schmiedebergs Arch Pharmacol (1984) 0.90
S100A1 deficiency results in prolonged ventricular repolarization in response to sympathetic activation. Gen Physiol Biophys (2008) 0.89
The glycosyl phosphatidylinositol anchor of human T-cadherin binds lipoproteins. Biochem Biophys Res Commun (2000) 0.88
Platelet membrane calmodulin-stimulated calcium-adenosine triphosphatase. Altered activity in essential hypertension. Hypertension (1986) 0.87
Age, race, blood pressure and renin: predictors for antihypertensive treatment with calcium antagonists. Am J Cardiol (1985) 0.87
Calcium transients in human platelets monitored by aequorin, fura-2 and quin-2: effects of protein kinase C activation and inhibition. Biochem Biophys Res Commun (1987) 0.86
Human cardiac plasma concentrations of atrial natriuretic peptide quantified by radioreceptor assay. Biochem Biophys Res Commun (1985) 0.86
LDL binds to surface-expressed human T-cadherin in transfected HEK293 cells and influences homophilic adhesive interactions. FEBS Lett (1999) 0.86
Free calcium concentration in platelets closely relates to blood pressure in normal and essentially hypertensive subjects. Hypertension (1984) 0.86
Calcium antagonists and the second drug for hypertensive therapy. Am J Med (1986) 0.86
Urokinase plasminogen activator enhances neointima growth and reduces lumen size in injured carotid arteries. J Hypertens (2000) 0.86
Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms. Mol Cell Biochem (1999) 0.86
Activation of phosphatidylinositol-specific phospholipase C in response to HDL3 and LDL is markedly reduced in cultured fibroblasts from Tangier patients. Arterioscler Thromb Vasc Biol (1995) 0.86
The interaction of aminogroups with pyrroloquinoline quinone as detected by the reduction of nitroblue tetrazolium. Biochem Biophys Res Commun (1988) 0.85
High-density lipoprotein and low-density lipoprotein-mediated signal transduction in cultured human skin fibroblasts. Cell Signal (1995) 0.85
(-)-Adrenaline-induced, calcium-dependent phosphorylation of proteins in human platelets. J Clin Invest (1985) 0.84
Rapid intracellular release of calcium in human platelets by stimulation of 5-HT2-receptors. Br J Pharmacol (1985) 0.84
Effect of tumour-promoting phorbol ester, thrombin and vasopressin on translocation of three distinct protein kinase C isoforms in human platelets and regulation by calcium. Biochem J (1992) 0.84
Hemodynamic and reflex responses to acute and chronic antihypertensive therapy with the calcium entry blocker nifedipine. Hypertension (1983) 0.83
Excitatory and inhibitory modulation of intracellular free calcium in human platelets by hormones and drugs. Eur J Pharmacol (1983) 0.83
Localization of the angiotensin II receptor subtypes in the human atrium. J Mol Cell Cardiol (1996) 0.82
T-cadherin loss induces an invasive phenotype in human keratinocytes and squamous cell carcinoma (SCC) cells in vitro and is associated with malignant transformation of cutaneous SCC in vivo. Br J Dermatol (2010) 0.82
Translocation of protein kinase C is not required to inhibit the antigen-induced increase of cytosolic calcium in a mast cell line. Biochem Biophys Res Commun (1987) 0.82
Phosphoinositide and calcium signalling responses in smooth muscle cells: comparison between lipoproteins, Ang II, and PDGF. Biochem Biophys Res Commun (1992) 0.82
Femoral neck fatigue fracture. Arch Orthop Trauma Surg (1980) 0.82
Antihypertensive therapy with the long-acting calcium antagonist nitrendipine. J Cardiovasc Pharmacol (1984) 0.82
Measurement of receptor induced changes in intracellular free calcium in human platelets. J Recept Res (1984) 0.81
Trends in reperfusion therapy of ST segment elevation myocardial infarction in Switzerland: six year results from a nationwide registry. Heart (2005) 0.81
Use of calcium antagonists as monotherapy in the management of hypertension. Am J Med (1984) 0.81
Ca(2+)-channel blockers modulate expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor genes stimulated by platelet-derived growth factor. Proc Natl Acad Sci U S A (1991) 0.81
Adrenoceptors, calcium, and vasoconstriction in normal and hypertensive humans. J Cardiovasc Pharmacol (1985) 0.81
Quantitation of glycosylated hemoglobin by boronate affinity chromatography. Diabetes (1984) 0.81
Use of drugs with more than a twenty-four-hour duration of action. J Hypertens Suppl (1994) 0.81
Position of calcium antagonists in antihypertensive therapy. J Cardiovasc Pharmacol (1985) 0.81
Evaluation of the fructosamine test for the measurement of plasma protein glycation. Diabetologia (1987) 0.80
Inositol 1,4,5-trisphosphate-induced calcium release in permeabilized platelets is coupled to hydrolysis of inositol 1,4,5-trisphosphate to inositol 1,4-bisphosphate. Biochem Biophys Res Commun (1993) 0.80
Activation of human blood platelets by arginine-vasopressin. Role of bivalent cations. Mol Pharmacol (1985) 0.80
Anomalous right coronary artery originating from the mid left main coronary artery. Heart (2003) 0.79
Atrial antipressor natriuretic peptide: release mechanisms and vascular action in man. J Hypertens Suppl (1986) 0.79
The influence of CGP 28392, a 1,4-dihydropyridine, on human platelet calcium and cyclic AMP metabolism. Eur J Pharmacol (1985) 0.79
Is transesophageal echocardiography still necessary to exclude patent foramen ovale? Scand Cardiovasc J (2008) 0.79
Vasopressin-induced activation of human blood platelets: prominent role of Mg2+. Naunyn Schmiedebergs Arch Pharmacol (1985) 0.79
Effects of mibefradil on intracellular Ca2+ release in cultured rat cardiac fibroblasts and human platelets. Naunyn Schmiedebergs Arch Pharmacol (1995) 0.79
High T-cadherin expression is a feature of basal cell carcinoma. Br J Dermatol (2009) 0.78
Serum procalcitonin has the potential to identify Staphylococcus aureus endocarditis. Eur J Clin Microbiol Infect Dis (2008) 0.78
The adrenaline-alpha 2-adrenoceptor-mediated vasoconstrictor axis. Clin Sci (Lond) (1985) 0.78
Identification of AT1 receptors on human platelets and decreased angiotensin II binding in hypertension. J Hypertens Suppl (1993) 0.78
[Pravastatin in the treatment of primary hypercholesterolemia: a Swiss multicenter study]. Schweiz Med Wochenschr (1993) 0.78
Involvement of protein kinase C in hypoxia-induced desensitization of the beta-adrenergic system in human endothelial cells. Biochem Biophys Res Commun (1996) 0.78
Effects of calcium antagonists on atherogenesis. Clin Exp Hypertens A (1989) 0.78
Monocyte integrin expression and monocyte-platelet complex formation in humans with coronary restenosis. Clin Exp Pharmacol Physiol (2001) 0.77
Vasodilating agents and platelet function: intracellular free calcium concentration, cyclic nucleotides, and shape-change response. J Cardiovasc Pharmacol (1986) 0.77
Effect of moderate weight reduction on resting and exercise blood pressure in overweight subjects. J Hum Hypertens (2007) 0.77
[Temporal trends in treatment of ST segment elevation myocardial infarction in Switzerland from 1997 to 2005]. Rev Med Suisse (2006) 0.77
Regulation of inositol 1,4,5-trisphosphate-induced calcium release by inositol 1,4,5-trisphosphate and calcium in human platelets. J Recept Signal Transduct Res (1997) 0.77
Abnormal cellular calcium regulation in essential hypertension. J Cardiovasc Pharmacol (1986) 0.77
Urokinase plasminogen activator system in humans with stable coronary artery disease. Clin Exp Pharmacol Physiol (1999) 0.77
Free calcium response to adrenaline in platelets of normal and hypertensive (untreated and treated) subjects. J Hypertens Suppl (1984) 0.76
Prediction of hypertensive crisis based on average, variability and approximate entropy of 24-h ambulatory blood pressure monitoring. J Hum Hypertens (2007) 0.76